TG Therapeutics Shares Rise 27% After 1Q Revenue Beat

Dow Jones05-01

By Sabela Ojea

Shares of TG Therapeutics on Wednesday jumped after the company reported first-quarter revenue in the first quarter.

The stock was up 27% to $17.29 in pre-market trading.

TG Therapeutics reported revenue for the quarter of $63.5 million, up from $7.8 million for the same period a year earlier, and ahead of the $54.6 million expected by Wall Street, according to FactSet.

The company also posted a net loss of $10.7 million, or 7 cents a share, compared with a loss of $39.2 million, or 28 cents, a year ago.

Regarding its outlook, TG Therapeutics said it expects to end 2024 with $270 million to $290 million in BRIUMVI U.S. net revenue, up from $220 million to $260 million previously.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 01, 2024 08:50 ET (12:50 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432579624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-01 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432579624","market":"sh","top_or_hot":-1,"title":"TG Therapeutics Shares Rise 27% After 1Q Revenue Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Wednesday jumped after the company reported first-quarter revenue in the first quarter. \n</p>\n<p>\n  The stock was up 27% to $17.29 in pre-market trading. \n</p>\n<p>\n  TG Therapeutics reported revenue for the quarter of $63.5 million, up from $7.8 million for the same period a year earlier, and ahead of the $54.6 million expected by Wall Street, according to FactSet. \n</p>\n<p>\n  The company also posted a net loss of $10.7 million, or 7 cents a share, compared with a loss of $39.2 million, or 28 cents, a year ago. \n</p>\n<p>\n  Regarding its outlook, TG Therapeutics said it expects to end 2024 with $270 million to $290 million in BRIUMVI U.S. net revenue, up from $220 million to $260 million previously. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2024 08:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Shares Rise 27% After 1Q Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Shares Rise 27% After 1Q Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-01 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sabela Ojea \n\n\n \n\n\n  Shares of TG Therapeutics on Wednesday jumped after the company reported first-quarter revenue in the first quarter. \n\n\n  The stock was up 27% to $17.29 in pre-market trading. ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TG","symbol_name":"特里迪加","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2432579624","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432579624","pubTimestamp":1714567800,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of TG Therapeutics on Wednesday jumped after the company reported first-quarter revenue in the first quarter.The stock was up 27% to $17.29 in pre-market trading.TG Therapeutics reported revenue for the quarter of $63.5 million, up from $7.8 million for the same period a year earlier, and ahead of the $54.6 million expected by Wall Street, according to FactSet.The company also posted a net loss of $10.7 million, or 7 cents a share, compared with a loss of $39.2 million, or 28 cents, a year ago.Regarding its outlook, TG Therapeutics said it expects to end 2024 with $270 million to $290 million in BRIUMVI U.S. net revenue, up from $220 million to $260 million previously.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TG":"特里迪加","TGTX":"TG Therapeutics Inc."},"translate_title":"TG Therapeutics股价上涨27%，1Q营收超过预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1,"TGTX":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of TG Therapeutics on Wednesday jumped after the company reported first-quarter revenue in the first quarter. \n\n\n  The stock was up 27% to $17.29 in pre-market trading. \n\n\n  TG Therapeutics reported revenue for the quarter of $63.5 million, up from $7.8 million for the same period a year earlier, and ahead of the $54.6 million expected by Wall Street, according to FactSet. \n\n\n  The company also posted a net loss of $10.7 million, or 7 cents a share, compared with a loss of $39.2 million, or 28 cents, a year ago. \n\n\n  Regarding its outlook, TG Therapeutics said it expects to end 2024 with $270 million to $290 million in BRIUMVI U.S. net revenue, up from $220 million to $260 million previously. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2024 08:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432579624"}